Skip to main content
Premium Trial:

Request an Annual Quote

Curetis Receives €350K German Government Grant to Develop Carbapenem Resistance Test

NEW YORK – OpGen said on Wednesday that its subsidiary Curetis has received more than €350,000 ($410,000) from the Federal German Ministry of Education and Research to use artificial intelligence for developing a test for carbapenem resistance in Gram-negative bacteria.

The project includes Curetis, based in Holzgerlingen, Germany, and collaborators at the Research Campus InfectoGnostics and is coordinated by Jena University Hospital. Curetis alone received €350,000 for the project, which is expected to start this month and run until August 2025.

The project also intends to address resistance mechanisms in "difficult-to-treat gram-negative pathogens such as Enterobacteria, Pseudomonas, and Acinetobacter," OpGen said in a statement. Curetis will provide research on "innovative detection methods" for carbapenem resistance based on porin loss and efflux pump overexpression.

"Carbapenems are last-resort antibiotics for treatment of patients infected with Gram-negative bacteria that show resistance against cephalosporins," said Gerd Luedke, director of innovation, technology and IP at Curetis, in a statement. "Resistance is often conferred by mechanisms such as porin loss or efflux pump overexpression, not adequately covered by current diagnostics."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.